Sökning: WFRF:(Stender Steen)
> (2002-2004) >
Effects of rosuvast...
Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia
-
- Olsson, Anders, 1940- (författare)
- Östergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Internmedicin,EMK-endokrin
-
Istad, Helge (författare)
-
Luurila, Olavi (författare)
-
visa fler...
-
Ose, Leiv (författare)
-
Stender, Steen (författare)
-
Tuomilehto, Jaakko (författare)
-
Wiklund, Olov (författare)
-
Southworth, Harry (författare)
-
Pears, John (författare)
-
Wilpshaar, J W (författare)
-
visa färre...
-
(creator_code:org_t)
- Elsevier BV, 2002
- 2002
- Engelska.
-
Ingår i: American Heart Journal. - : Elsevier BV. - 0002-8703 .- 1097-6744. ; 144:6, s. 1044-1051
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: Despite the demonstrated benefits of low-density lipoprotein cholesterol (LDL-C) reduction in reducing the risk of coronary heart disease, many patients receiving lipid-lowering therapy fail to achieve LDL-C goals. We compared the effects of rosuvastatin and atorvastatin in reducing LDL-C and achieving LDL-C goals in patients with primary hypercholesterolemia. Methods and Results: In this 52-week, randomized, double-blind, multicenter trial (4522IL/0026), 412 patients with LDL-C 160 to <250 mg/dL received a 5-mg dose of rosuvastatin (n = 138), a 10-mg dose of rosuvastatin (n = 134), or a 10-mg dose of atorvastatin (n = 140) for 12 weeks, during the following 40 weeks, dosages could be sequentially doubled up to 80 mg if National Cholesterol Education Program Adult Treatment Panel II (ATP-II) LDL-C goals were not achieved. At 12 weeks, 5- and 10-mg doses of rosuvastatin were associated with significantly greater LDL-C reductions than 10-mg doses of atorvastatin (46% and 50% vs 39%, both P < .001). At 12 weeks, both rosuvastatin dosages brought more patients to within ATP-II and European LDL-C goals than atorvastatin (86% and 89% vs 73% and 75%, and 86% vs 55%, respectively). At 52 weeks, compared with atorvastatin, both initial rosuvastatin treatment groups significantly reduced LDL-C (47% and 53% vs 44%, P < .05 and P < .001). Overall, more patients in the initial rosuvastatin 10-mg group achieved their ATP-II LDL-C goal than those in the initial atorvastatin 10-mg group (98% vs 87%), with 82% of patients treated with rosuvastatin achieving their goal at the 10-mg starting dosage without the need for titration, compared with 59% of patients treated with atorvastatin. Both treatments were well tolerated over 52 weeks. Conclusion: Compared with atorvastatin, rosuvastatin produced greater reductions in LDL-C, which may offer advantages in LDL-C goal attainment over existing lipid-lowering therapies.
Nyckelord
- MEDICINE
- MEDICIN
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Olsson, Anders, ...
-
Istad, Helge
-
Luurila, Olavi
-
Ose, Leiv
-
Stender, Steen
-
Tuomilehto, Jaak ...
-
visa fler...
-
Wiklund, Olov
-
Southworth, Harr ...
-
Pears, John
-
Wilpshaar, J W
-
visa färre...
- Artiklar i publikationen
-
American Heart J ...
- Av lärosätet
-
Linköpings universitet